171 related articles for article (PubMed ID: 38339195)
1. Stratification of Colorectal Patients Based on Survival Analysis Shows the Value of Consensus Molecular Subtypes and Reveals the CBLL1 Gene as a Biomarker of CMS2 Tumours.
Alfonsín G; Berral-González A; Rodríguez-Alonso A; Quiroga M; De Las Rivas J; Figueroa A
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339195
[TBL] [Abstract][Full Text] [Related]
2. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
3. CBLL1 is highly expressed in non-small cell lung cancer and promotes cell proliferation and invasion.
Hui L; Zhang S; Wudu M; Ren H; Xu Y; Zhang Q; Qiu X
Thorac Cancer; 2019 Jun; 10(6):1479-1488. PubMed ID: 31124298
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
Qiu HB; Yang K; Yu HY; Liu M
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
[TBL] [Abstract][Full Text] [Related]
5. A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype.
Fessler E; Jansen M; De Sousa E Melo F; Zhao L; Prasetyanti PR; Rodermond H; Kandimalla R; Linnekamp JF; Franitza M; van Hooff SR; de Jong JH; Oppeneer SC; van Noesel CJ; Dekker E; Stassi G; Wang X; Medema JP; Vermeulen L
Oncogene; 2016 Nov; 35(46):6026-6037. PubMed ID: 27157610
[TBL] [Abstract][Full Text] [Related]
6. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
[TBL] [Abstract][Full Text] [Related]
7. CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin.
Xu J; Zhou J; Dai H; Liu F; Li W; Wang W; Guo F
J Transl Med; 2018 Jun; 16(1):169. PubMed ID: 29921293
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
De Smedt L; Palmans S; Andel D; Govaere O; Boeckx B; Smeets D; Galle E; Wouters J; Barras D; Suffiotti M; Dekervel J; Tousseyn T; De Hertogh G; Prenen H; Tejpar S; Lambrechts D; Sagaert X
Br J Cancer; 2017 Jan; 116(1):58-65. PubMed ID: 27884016
[TBL] [Abstract][Full Text] [Related]
9. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
[TBL] [Abstract][Full Text] [Related]
10. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
[TBL] [Abstract][Full Text] [Related]
11. Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?
Albuquerque C; Pebre Pereira L
Adv Exp Med Biol; 2018; 1110():75-100. PubMed ID: 30623367
[TBL] [Abstract][Full Text] [Related]
12. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
[TBL] [Abstract][Full Text] [Related]
13. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
[TBL] [Abstract][Full Text] [Related]
14. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
[TBL] [Abstract][Full Text] [Related]
15. Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study.
González-Montero J; Burotto M; Valenzuela G; Mateluna D; Buen-Abad F; Toro J; Barajas O; Marcelain K
World J Clin Oncol; 2023 Oct; 14(10):409-419. PubMed ID: 37970108
[TBL] [Abstract][Full Text] [Related]
16. Cofilin-1, LIMK1 and SSH1 are differentially expressed in locally advanced colorectal cancer and according to consensus molecular subtypes.
Sousa-Squiavinato ACM; Vasconcelos RI; Gehren AS; Fernandes PV; de Oliveira IM; Boroni M; Morgado-Díaz JA
Cancer Cell Int; 2021 Jan; 21(1):69. PubMed ID: 33482809
[TBL] [Abstract][Full Text] [Related]
17. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.
Le Corre D; Ghazi A; Balogoun R; Pilati C; Aparicio T; Martin-Lannerée S; Marisa L; Djouadi F; Poindessous V; Crozet C; Emile JF; Mulot C; Le Malicot K; Boige V; Blons H; de Reynies A; Taieb J; Ghiringhelli F; Bennouna J; Launay JM; Laurent-Puig P; Mouillet-Richard S
EBioMedicine; 2019 Aug; 46():94-104. PubMed ID: 31377347
[TBL] [Abstract][Full Text] [Related]
18. Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype.
Cherradi S; Martineau P; Gongora C; Del Rio M
Cancer Manag Res; 2019; 11():1337-1348. PubMed ID: 30863148
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of mesenchymal colon tumour-derived cells in tumourspheres as a model for colorectal cancer progression.
Turano M; Costabile V; Cerasuolo A; Duraturo F; Liccardo R; Delrio P; Pace U; Rega D; Dodaro CA; Milone M; Izzo P; De Rosa M
Int J Oncol; 2018 Dec; 53(6):2379-2396. PubMed ID: 30272331
[TBL] [Abstract][Full Text] [Related]
20. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
